Display options
Cite
van Hattem WA, Carvalho R, Li A, et al. Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. Int J Clin Exp Pathol. 2008;1(4):343-51
van Hattem, W. A., Carvalho, R., Li, A., Offerhaus, G. J., & Goggins, M. (2008). Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. International journal of clinical and experimental pathology, 1(4), 343-51.
van Hattem, W Arnout, et al. "Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas." International journal of clinical and experimental pathology vol. 1,4 (2008): 343-51.
van Hattem WA, Carvalho R, Li A, Offerhaus GJ, Goggins M. Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. Int J Clin Exp Pathol. 2008 Jan 01;1(4):343-51. PMID: 18787609; PMCID: PMC2480540.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Pathol. 2008 Jan 01;1(4):343-51.

Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas.

International journal of clinical and experimental pathology

W Arnout van Hattem, Ralph Carvalho, Ang Li, G Johan A Offerhaus, Michael Goggins

Affiliations

  1. Departments of Oncology Center, The Sol Goldman Pancreatic Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands, and the University Medical Center, Utrecht, the Netherlands.

PMID: 18787609 PMCID: PMC2480540

Abstract

Mutations in the breast cancer susceptibility gene 2 (BRCA2) are commonly found in familial pancreatic cancer. Recently, EMSY (11q13.5) has been described as a BRCA2 interacting protein capable of binding and inactivating the protein domain encoded by exon 3 of the BRCA2 gene. Amplification of EMSY occurs in 13% of sporadic breast cancers and is directly linked to increased expression. Here we investigate the amplification status of this new potential oncogene in 59 sporadic pancreatic cancers using fluorescence in situ hybridization (FISH) and tissue microarray (TMA). Real-time quantitative RT-PCR was performed on 20 pancreatic cancer cell lines and overexpression was calculated using the delta-delta-Ct-method. Amplification of EMSY was found in 8/59 cases (13.6%). 9/20 (45%) cell line samples showed overexpression of EMSY. In conclusion, sporadic pancreatic cancer shows amplification of EMSY at prevalence similar to that found in other cancers.

Keywords: BRCA2; EMSY; FISH; Pancreatic cancer; amplification

References

  1. Cell. 2003 Nov 26;115(5):523-35 - PubMed
  2. Cancer Cell. 2002 Jul;2(1):25-8 - PubMed
  3. J Hepatobiliary Pancreat Surg. 2006;13(4):286-95 - PubMed
  4. Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):342-6 - PubMed
  5. Oncogene. 2005 May 19;24(22):3652-6 - PubMed
  6. Oncogene. 2005 Jan 27;24(5):850-8 - PubMed
  7. Cancer Biol Ther. 2005 Jul;4(7):703-6 - PubMed
  8. Cancer. 1995 Nov 1;76(9):1671-7 - PubMed
  9. Genes Chromosomes Cancer. 1994 Jan;9(1):42-8 - PubMed
  10. Structure. 2006 Apr;14(4):703-12 - PubMed
  11. Cytogenet Cell Genet. 1997;79(1-2):125-31 - PubMed
  12. Cell Death Differ. 2007 May;14(5):924-31 - PubMed
  13. Cancer Res. 2003 May 15;63(10):2585-8 - PubMed
  14. J Med Genet. 2004 Dec;41(12):e126 - PubMed
  15. Clin Cancer Res. 2007 May 1;13(9):2728-37 - PubMed
  16. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5950-4 - PubMed
  17. Cell. 2002 Jan 25;108(2):171-82 - PubMed
  18. Cancer Res. 2006 Aug 15;66(16):8109-15 - PubMed
  19. J Clin Oncol. 2002 Dec 1;20(23):4531-42 - PubMed
  20. Nature. 1997 Apr 24;386(6627):804-10 - PubMed
  21. Nature. 2005 Apr 14;434(7035):917-21 - PubMed
  22. Am J Pathol. 2004 Aug;165(2):651-7 - PubMed
  23. Am J Pathol. 2000 May;156(5):1767-71 - PubMed
  24. J Mol Biol. 2005 Jul 29;350(5):964-73 - PubMed
  25. J Clin Oncol. 2007 Jan 20;25(3):319-25 - PubMed
  26. Gynecol Oncol. 2006 Feb;100(2):264-70 - PubMed
  27. Gastroenterology. 2006 Feb;130(2):548-65 - PubMed
  28. Clin Cancer Res. 2007 Jan 1;13(1):4-10 - PubMed
  29. Cancer Res. 2000 Apr 1;60(7):1835-9 - PubMed
  30. Ann Surg. 1998 Jun;227(6):821-31 - PubMed
  31. Nature. 2005 Apr 14;434(7035):913-7 - PubMed
  32. Cancer Res. 2005 May 15;65(10):4117-25 - PubMed
  33. Oncogene. 1998 Aug 27;17(8):1053-9 - PubMed
  34. Oncogene. 2003 Aug 7;22(32):5021-30 - PubMed
  35. Neoplasia. 2005 Jun;7(6):556-62 - PubMed
  36. Cancer Biol Ther. 2004 Feb;3(2):167-9 - PubMed
  37. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9 - PubMed
  38. Cancer Res. 1998 Apr 1;58(7):1372-5 - PubMed
  39. EMBO J. 2001 Sep 3;20(17):4704-16 - PubMed
  40. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8644-9 - PubMed
  41. Lancet. 1997 May 24;349(9064):1505-10 - PubMed
  42. J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 - PubMed
  43. Cancer Biol Ther. 2005 Sep;4(9):934-6 - PubMed
  44. Clin Cancer Res. 2004 Sep 1;10(17):5785-91 - PubMed
  45. Mol Cell. 1998 Feb;1(3):347-57 - PubMed
  46. Cancer Res. 2005 Nov 15;65(22):10145-8 - PubMed
  47. Cancer Res. 2002 Jul 1;62(13):3789-93 - PubMed
  48. Cancer Res. 2005 Jan 15;65(2):383-6 - PubMed
  49. CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 - PubMed
  50. EMBO Rep. 2005 Jul;6(7):675-80 - PubMed
  51. J Hepatobiliary Pancreat Surg. 2006;13(4):280-5 - PubMed
  52. Clin Cancer Res. 2005 Oct 15;11(20):7508-15 - PubMed
  53. Clin Cancer Res. 2001 Dec;7(12):4115-21 - PubMed
  54. Cancer Res. 1996 Dec 1;56(23):5360-4 - PubMed
  55. J Natl Cancer Inst. 1998 Jul 1;90(13):978-85 - PubMed
  56. J Natl Cancer Inst. 2005 Sep 7;97(17):1302-6 - PubMed

Publication Types

Grant support